Mortality associated with bloodstream infections increased
lated. This study examined direct medical expenditures for hospitalization, provider services, tests, procedures, and mediby 83%, from 4.2 to 7.7 per 100,000 persons, between 1980 and 1992 [1] , in spite of predictions that it would decrease.
cations. Indirect costs such as work days and productivity lost Bloodstream infections accounted for Ç12% of infectious disbecause of morbidity and mortality were not included. ease deaths and 1% of all deaths in 1992. The causes of this An episode of care for the treatment of candidemia was increase include a rise in the number of immunocompromised defined in order to assess the costs of treating an individual organ or bone marrow transplant recipients and HIV-infected patient in the United States. This cost of care was then applied patients as well as patients requiring antibiotic therapy leading to the yearly population of patients who develop nosocomial to superinfection [1] .
systemic candidal infections, to determine the annual cost of The pathogens responsible for this increasing mortality rate candidemia for the U.S. population. include coagulase-negative staphylococci, Staphylococcus Data were obtained from three sources. The 1993 Healthcare aureus, and Enterococcus and Candida species [2] . Candida is Cost and Utilization Project (HCUP-3) [10] of the Agency for now the fourth most common cause of nosocomial bloodstream Health Care Policy and Research provided information on the infections, accounting for 7% -15% of these events [2 -6] . The marginal increase in hospital stay due to candidemia. Treatment literature indicates that Candida albicans is the most common patterns and resource utilization for episodes of candidemia of the Candida species causing bloodstream infection, most were determined on the basis of a review of the literature. frequently associated with the use of antibiotics and central Finally, we consulted an expert in the treatment of systemic catheters/iv lines [3, 4, 7 -9] .
fungal infections to verify treatment of adverse reactions to Although numerous studies have examined the clinical and antifungal therapy and the probability of discontinuation of epidemiological trends in nosocomial fungal infections, none have therapy because of these adverse reactions. specifically studied the cost of care associated with candidemia. This study analyzes the direct medical costs associated with treatHospitalization Due to Candidemia ing candidemia diagnosed during a hospital stay in the United States. The study design was a cost-of-illness analysis estimating
Patients are generally not admitted to the hospital with candithe average cost of candidemia over a single episode of care. demia; rather, it develops in a subset of patients who are hospitalized for other reasons. Therefore, we evaluated the marginal Methods increase in length of hospitalization due to candidemia with A cost-of-illness study examines total costs for an illness, use of data from the 1993 Nationwide Inpatient Sample (NIS, cost drivers, and resource categories in which costs are accumurelease 2), a component of HCUP-3. Although these data are from 1993, they were not publicly released until late 1996. At this time, the NIS-HCUP-3 database became the newest, most the NIS summarizes a patient's hospital stay with use of inforwas then used to determine the costs associated with adverse event treatments. mation from the patient's medical record or bill, documenting patient characteristics such as age, race, and gender, as well as medical information, including specific diagnoses and proceAnnual Incident Population dures.
To determine the marginal increase in length of hospitalizaThe yearly population of patients who experience candidemia in the United States was determined with data from the tion due to candidemia, patients were identified with use of the discharge diagnosis of candidemia (code 112.5 in the Inter-1990 National Health Interview Survey (NHIS) [16] and the 1990 National Hospital Discharge Survey (NHDS) [17] . The national Classification of Diseases, 9th revision). A total of 1,624 patients, classified in 177 different diagnosis-related NHIS is an annual survey administered by the U.S. Department of Health and Human Services, National Center for Health groups (DRGs), were found. Patients with similar clinical classifications were grouped together to form seven different diagStatistics (NCHS). The NHIS collects information from the noninstitutionalized, civilian U.S. population. Data on sociodenosis categories (neoplasms, infectious diseases, circulatory problems, gastrointestinal conditions, respiratory conditions, mographic and health characteristics are collected from all members of selected households. The 1990 NHIS included injury and poisoning, and miscellaneous). A control group of patients was randomly selected from all patients without candi-43,007 households with 109,671 persons. Weights are included with the survey data to produce nationally representative estidemia, with DRG, gender, and age group matching those of the patients with candidemia. Three matched controls were mates. The NHDS, also performed by the NCHS, is a nationally selected for each candidemia patient. Patients were not matched for severity or intensive care unit (ICU) status, as this level of representative survey of hospital discharges in all 50 states and the District of Columbia. It records information on a sample data is not available in the NIS database.
In spite of the matched control group, significant demoof hospitalizations from nonfederal, short-stay hospitals during a given year. The 1990 survey included 235,947 discharges graphic or diagnosis differences may exist between these patients and the candidemia patients. To control for these differfrom 474 hospitals. From the NHIS, the proportion of individuals hospitalized in the United States during 1990 was deterences and determine a more accurate measurement of the impact of candidemia on length of stay (LOS), we developed mined. We then used weighted estimates from the NHDS to determine the probability that a hospitalized patient would dea linear regression model. The model does not predict overall LOS but determines the influence of candidemia on LOS while velop candidemia. The annual incidence of candidemia was determined to be 2.43 per 100,000 population. Applying this controlling for age, gender, discharge status, and diagnostic category. Age was stratified into a four-level variable: õ15 rate to the U.S. population of 260 million people, we estimated the annual incidence to be Ç6,326 cases. years of age; 15 -44 years of age; 45 -64 years of age; and §65 years of age.
Assignment of Charges
The episode of care for this study included medical charges Treatment Patterns and Resource Utilization for treatment of candidemia and for treatment of adverse events associated with therapy for candidemia during a single hospitalTo assess medical resource utilization and outcomes for patients with candidemia, we reviewed the relevant literature.
ization. These included fees for antifungal medications, diagnostic and monitoring tests and examinations, and additional Studies were assessed with regard to quality, appropriateness, and methodology; we included only credible studies that specidays of hospitalization due to candidemia (both Medicare and private sector charges were used). All charges were calculated fied inclusion and exclusion criteria, types of infections, outcome measures, and results for all enrolled patients. in 1997 U.S. dollars, with use of the medical component of the Consumer Price Index inflator where necessary. The charge Probabilities obtained from the literature included use of diagnostic procedures, types of antifungal therapy, receipt of for each resource used was determined by multiplying the unit charge for the resource (e.g., the fee for a single procedure or a given type of antifungal therapy, and occurrence of specific adverse events [3, 4, 7, 9, 11 -15] . When more than one source test) by the frequency of use. Charges associated with each of these utilization categories were gathered from the sources of data was available for these probabilities, a weighted pointestimate was determined. discussed below. Charges for diagnostic tests, procedures, and laboratory tests Expert opinion was used only when we could not otherwise obtain necessary information. Parameters estimated with use of were assigned by means of a fee schedule developed by Health Care Consultants of America, Inc.
[18]. For each test and proceexpert opinion included laboratory testing for patients receiving amphotericin B; treatment patterns for adverse reactions to dure, estimates of covered charges are provided for Medicare and private-pay patients. The national average allowance is the antifungal therapy; and the probability of discontinuation of antifungal therapy because of adverse events. This information average amount reimbursed by Medicare, based on its resource-/ 9C57$$oc46 09-15-98 17:57:58 cida UC: CID Table 1 illustrates the demographic similarities and differences between the control and candidemia groups. The only statistically significant differences between the candidemia and noncandidemia patients were in the patient discharge status LOS for the control group was determined by weighting the mean LOS for patients in each diagnosis category by the proand the diagnosis category groups of infectious disease and circulatory conditions. There were no significant differences portion of candidemia patients in the corresponding category. Table 2 presents information on average LOS for the candidebetween the patient groups with regard to sex, age category, or the remaining diagnosis categories. In addition, no significant mia and control groups. Separate LOS values are presented for each diagnosis category; a weighted average is then presented differences existed between the immunosuppressed candidemia and control groups (HIV-positive patients or bone marrow or for the control group, based on the proportion of candidemia patients in each diagnosis category. For all diagnosis categories organ transplant recipients). The proportion of patients who were immunosuppressed is relatively small, given that systemic combined, the marginal increase in LOS for candidemia patients over control patients was 21.6 days. The difference varies fungal infections are frequent in this patient population and may be underrepresented. This may be due to the fact that between diagnosis categories but is statistically significant for all. several states in the NIS sample refused to release the HIV infection status for patients at tertiary care centers, where the Second, to control for factors that may influence LOS, we used regression analysis to determine the impact of candidemia sickest patients are usually hospitalized.
on the hospital LOS. Table 3 presents results from the linear regression examining LOS.
Impact of Candidemia
Overall, candidemia had a major impact on LOS; patients who developed candidemia had an average of ú34 more days Length of hospital stay due to candidemia was defined as the difference in LOS between patients with candidemia and of hospitalization than did control patients. This increased LOS is highly statistically significant (P õ .0001) and is greater control group patients, with use of two different methods. First, / 9C57$$oc46 09-15-98 17:57:58 cida UC: CID Details regarding adverse drug reactions to fluconazole or represents the finding that this regression model with these amphotericin B are presented in table 6. Since HCUP-3 is an variables explains 20% of the variation in LOS. Older patients administrative database, we were unable to obtain adverse drug had a significantly longer LOS than did younger patients. Pareaction rates from it and therefore relied on the literature. Only tients who were discharged alive had a significantly shorter adverse events that resulted in treatment or discontinuation of length of hospitalization than did those who died before distherapy were included in the model. While elevated hepatic charge. There was no significant difference in LOS between enzyme levels are relatively common, this adverse event was males and females.
not included in the model because there is no associated treat- Table 3 also presents the impact of diagnosis category on ment and patients would not discontinue therapy. The probabil-LOS. The impact of each diagnosis category was examined ities for each adverse event presented in this table represent the with linear regression in comparison with the Miscellaneous probability among all patients using each antifungal therapy. Problems category. For example, patients who were hospitalTreatments for adverse events and the probability of disconized because of a diagnosed illness in the Circulatory Problems tinuation of therapy following each adverse event were not category had, on average, an LOS that was 6.44 days greater than that for patients hospitalized for a diagnosis from the Miscellaneous Problems category. With the exception of Infec- available from published studies, so these values were based therapy due to adverse events; these additional costs are presented in table 7 (see below). on the expert opinion of one of the authors (R. B.). The treatment costs represent weighted values for the entire candidemic population (e.g., the cost of treating nausea/vomiting is the cost The overall costs of illness are summarized in table 7. Separate costs are presented for Medicare and private-pay patients; and 30% for amphotericin B]). Two treatments were provided for fever/chills/rigors; therefore, we assumed that one-half of per-patient costs and annual costs are also presented separately. Annual costs are based on an incidence rate of 6,326 cases of the patients developing this adverse event receive each therapy (i.e., with amphotericin B, 15% of patients receive diphenhycandidemia per year, as discussed in the Methods section. The major cost associated with candidemia is that of indramine and 15% receive both meperidine and diphenhydramine). Costs for adverse event treatments were based on the creased hospital stay. This resource represents 85% -90% of the total costs for Medicare and private-pay patients. The next 1997 Red Book [19] average wholesale price.
Total costs for the treatment of adverse events are low. Howlargest cost item, antifungal therapy, represents only 7% -11% of the total. Diagnostic procedure costs are 3% of the total. ever, they are greater for patients receiving amphotericin B than for patients receiving fluconazole because of the greater
The cost for treating adverse drug reactions is the total cost of the adverse reaction treatment for both fluconazole and amincidence of adverse events caused by amphotericin B. The costs presented in table 6 represent only direct treatment for photericin patients, weighted by the proportion of patients in each therapy group. The total cost for treatment of adverse adverse events, not costs associated with discontinuation of events is trivial compared with costs associated with discontinAnnual costs follow the same patterns seen for per-patient costs. On the basis of the incidence figures used in this study, uation of therapy due to adverse events. For this model, we assumed that patients who ended therapy because of adverse we estimate that candidemia results in excess medical costs of $216 million to $281 million per year. events would do so at the midpoint of their antifungal treatment and that these patients would then receive a full course of therapy with the alternate medication. Discussion For example, patients who stopped receiving fluconazole therapy due to adverse events would do so after receiving the
The current cost-of-illness study is based on three sources of data. Initially, we constructed an episode of care, specifying drug for 8.0 days, when the full course of therapy was 16.0 days. They would then switch to amphotericin B and receive treatment patterns and resource utilization for candidemia by reviewing relevant literature. Next, we determined the marginal the full 19.1 days of therapy with this medication, for a total of 27.1 days of antifungal therapy. Similarly, patients who increase in hospitalization by comparing candidemic patients with noncandidemic patients in the 1993 HCUP-3. Treatment discontinued amphotericin therapy were assumed to have received 9.55 days of amphotericin B, followed by 16.0 days of of adverse events and the probability of discontinuation of therapy were based on current practices in the United States fluconazole, for a total of 25.55 days.
In table 7 , costs of switching therapy due to adverse drug during the time period of the study. Constructing the cost-of-illness model was necessary bereactions are weighted by the proportion of patients receiving fluconazole vs. amphotericin. These costs represent 1% of the cause data are not available on the full costs and outcomes associated with candidemia. To date, no agreement has been total cost of care associated with treatment of candidemia.
Costs for private insurance patients are approximately 30% reached concerning a standard treatment for patients with candidemia [3, 15, 22] . Some studies recommend treating all cangreater than costs for Medicare patients. This difference is largely due to the difference in cost of hospitalization ($37,681 didemic patients with antifungal medication [22, 23] , while others recommend treating only patients who have sustained vs. $30,274), as well as differential costs for antifungal therapy. In addition, there is wide variation in clinical practice regardrisk, or at high risk). ''At risk'' patients were defined as those receiving broad-spectrum antibacterials postoperatively. Highing the preferred medication, the dose, and the length of treatment with antifungal medications for candidemia. As a result, risk patients received treatment with broad-spectrum antibacterials and did not exhibit the expected clinical response. Comno clear episode of care is discussed in the literature. However, even as clinical practice changes, the data allow for assessment paring LOS and mean costs of the high-risk group to those of the not-at-risk group demonstrates an incremental increase in of these changes in the cost of care.
Controversy remains as to which drug is first-line therapy. LOS of 22 days and in total costs of $66,000. Differences between the study by Goff et al. [27] and ours Recently published results of a multicenter efficacy and effectiveness trial by Phillips et al. [26] comparing fluconazole to include patient population and candidemia-specific costs. Goff and colleagues did not compare patients with systemic candida amphotericin B for treating candidemia in nonneutropenic patients suggest that there is still a debate about these two therato those without, but patients at high risk for systemic candida to those not at risk. In addition, Goff et al. included all costs pies. Results of a recent international consensus conference on the management and prevention of severe candidal infection associated with a hospitalization in their economic analysis, while we attempted to isolate costs associated with treating suggest that first-line therapy may differ by patient population, disease severity, and previous exposure to antifungal medicasystemic candidal infection. These two cost studies clearly indicate that candidemia has tions [23] .
While there is agreement in the literature regarding the coma significant impact, as measured by medical resource utilization and costs, in the United States. Our results indicate a cost plications associated with amphotericin B, it was clearly the antifungal drug of choice for treating candidemia during the between $34,123 and $44,536 per individual case of candidemia. The need to care for hospitalized patients properly and to time period of the study. According to our weighted pointestimate from published studies, 71% of patients receive amprevent nosocomial infections from occurring assumes greater consequences in an era of health care reform, where the emphaphotericin B for treatment [3, 4, 9, 15, 16] . Consequently, overall treatment costs reflect the medical resources used in sis is on providing effective treatments while simultaneously lowering costs. Thus, new strategies to prevent systemic fungal treating amphotericin B complications and switching to alternative antifungal medications (in this case, fluconazole). Amphoinfections will be increasingly important. Although this study mainly used data through 1996, candidetericin B also has a longer infusion time than fluconazole, which leads to an increase in costs. When fluconazole use becomes mia and associated treatment patterns have not changed significantly. In the future, the greatest impact on cost of treatment more frequent, medication costs will increase, although costs associated with drug infusion time and rates of complications will be the availability of lipid-complexed amphotericin B, which, while associated with reduced adverse events (espefrom antifungal therapy are likely to decrease.
Although the literature discusses complications associated cially nephrotoxicity), costs 10 times as much as amphotericin B on a daily basis. Using lipid-complexed amphotericin B will with amphotericin B administered for candidemia, it does so only in very general terms and often does not present specific reduce costs associated with adverse events and discontinuation of therapy but will still result in an increase in overall cost of rates of or treatments for adverse reactions. Treatments for adverse reactions to antifungal medication and the probability care for candidemic patients. of discontinuation of therapy due to adverse reactions were based on information from one of the authors (R. B.). While
